NCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
7 trialsNCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
NCT06229912 2026-02-19
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07356154 2026-01-21
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT05406817 2025-01-10
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
Syndax Pharmaceuticals
Phase 1 Completed
NCT05326516 2024-08-13
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Syndax Pharmaceuticals
Phase 1 Completed